

# James J Rucker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9406360/publications.pdf>

Version: 2024-02-01

50  
papers

3,115  
citations

361045

20  
h-index

223531

46  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2023, 35, 77-85.	0.9	1
2	Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. <i>Human Brain Mapping</i> , 2022, 43, 300-328.	1.9	30
3	A narrative synthesis of research with 5-MeO-DMT. <i>Journal of Psychopharmacology</i> , 2022, 36, 273-294.	2.0	28
4	UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 487-495.	1.3	21
5	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. <i>Journal of Psychopharmacology</i> , 2022, 36, 114-125.	2.0	47
6	Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. <i>Journal of Psychopharmacology</i> , 2022, 36, 965-973.	2.0	22
7	UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 473-485.	1.3	21
8	Postpartum depression: A role for psychedelics?. <i>Journal of Psychopharmacology</i> , 2022, 36, 920-931.	2.0	2
9	Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). <i>Journal of Psychopharmacology</i> , 2022, 36, 956-964.	2.0	15
10	A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2021, 35, 501-511.	2.0	22
11	1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. <i>Translational Psychiatry</i> , 2021, 11, 182.	2.4	24
12	Psychedelics: Old drugs, new trips. <i>Journal of Psychopharmacology</i> , 2021, 35, 316-318.	2.0	0
13	Psilocybin and MDMA for the treatment of trauma-related psychopathology. <i>International Review of Psychiatry</i> , 2021, 33, 229-249.	1.4	46
14	Psilocybin: From Serendipity to Credibility?. <i>Frontiers in Psychiatry</i> , 2021, 12, 659044.	1.3	20
15	An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 362-370.	1.1	33
16	Ceremonial Ayahuasca in Amazonian Retreats – Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 687615.	1.3	25
17	Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. <i>CNS Drugs</i> , 2021, 35, 881-892.	2.7	10
18	International online survey of 1048 individuals with functional neurological disorder. <i>European Journal of Neurology</i> , 2021, 28, 3591-3602.	1.7	35

#	ARTICLE	IF	CITATIONS
19	Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis-Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1545-1554.	1.0	21
20	Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. <i>BMJ Open</i> , 2021, 11, e056091.	0.8	7
21	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. <i>Molecular Psychiatry</i> , 2020, 25, 584-602.	4.1	49
22	Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition. <i>JAMA Psychiatry</i> , 2020, 77, 420.	6.0	54
23	2020...International online survey of 1162 individuals with functional neurological disorder: demographics, symptom comorbidities, self-management strategies, and illness beliefs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, e16.1-e16.	0.9	0
24	Psychedelic treatment of functional neurological disorder: a systematic review. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532091212.	1.2	21
25	Historic psychedelic drug trials and the treatment of anxiety disorders. <i>Depression and Anxiety</i> , 2020, 37, 1261-1279.	2.0	23
26	Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts. <i>Biological Psychiatry</i> , 2019, 85, 1065-1073.	0.7	25
27	Psychiatry & the psychedelic drugs. Past, present & future. <i>Neuropharmacology</i> , 2018, 142, 200-218.	2.0	222
28	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. <i>Psychopharmacology</i> , 2018, 235, 399-408.	1.5	537
29	Interaction between the <i>FTO</i> gene, body mass index and depression: meta-analysis of 13701 individuals. <i>British Journal of Psychiatry</i> , 2017, 211, 70-76.	1.7	49
30	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. <i>Lancet Psychiatry</i> , 2016, 3, 619-627.	3.7	988
31	Psychedelics in the treatment of unipolar mood disorders: a systematic review. <i>Journal of Psychopharmacology</i> , 2016, 30, 1220-1229.	2.0	131
32	Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. <i>Biological Psychiatry</i> , 2016, 79, 329-336.	0.7	21
33	Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. <i>BMJ</i> , 2015, 350, h2902-h2902.	3.0	21
34	Mental Illness, Genetics of. , 2015, , 209-215.		0
35	A comparison of mental state examination documentation by junior clinicians in electronic health records before and after the introduction of a semi-structured assessment template (OPCRIT+). <i>International Journal of Medical Informatics</i> , 2015, 84, 675-682.	1.6	9
36	Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 303-313.	1.1	76

#	ARTICLE	IF	CITATIONS
37	Chipping away at major depressive disorder. <i>Genome Biology</i> , 2014, 15, 421.	3.8	4
38	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. <i>Pharmacogenomics Journal</i> , 2014, 14, 395-399.	0.9	20
39	Genome-wide association analysis of copy number variation in recurrent depressive disorder. <i>Molecular Psychiatry</i> , 2013, 18, 183-189.	4.1	45
40	A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients. <i>International Journal of Methods in Psychiatric Research</i> , 2013, 22, 110-137.	1.1	17
41	Harnessing Clinical Psychiatric Data with an Electronic Assessment Tool (OPCRIT+): The Utility of Symptom Dimensions. <i>PLoS ONE</i> , 2013, 8, e58790.	1.1	10
42	Male-Biased Autosomal Effect of 16p13.11 Copy Number Variation in Neurodevelopmental Disorders. <i>PLoS ONE</i> , 2013, 8, e61365.	1.1	101
43	Genomic structural variation in psychiatric disorders. <i>Development and Psychopathology</i> , 2012, 24, 1335-1344.	1.4	14
44	Depressive disorder moderates the effect of the FTO gene on body mass index. <i>Molecular Psychiatry</i> , 2012, 17, 604-611.	4.1	72
45	OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. <i>British Journal of Psychiatry</i> , 2011, 199, 151-155.	1.7	48
46	Polygenic Heterogeneity: A Complex Model of Genetic Inheritance in Psychiatric Disorders. <i>Biological Psychiatry</i> , 2010, 68, 312-313.	0.7	8
47	Mental capacity and psychiatric in-patients: implications for the new mental health law in England and Wales. <i>British Journal of Psychiatry</i> , 2009, 195, 257-263.	1.7	36
48	Why do we need to understand the molecular basis of depression?. <i>Biomarkers in Medicine</i> , 2008, 2, 101-104.	0.6	0
49	A Case of Prolonged Seizure After ECT in a Patient Treated With Clomipramine, Lithium, L-Tryptophan, Quetiapine, and Thyroxine for Major Depression. <i>Journal of ECT</i> , 2008, 24, 272-274.	0.3	12
50	Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	70